844502-63-2

Basic information

• Product Name: 3,4-THIOPHENEDICARBOXYLIC ACID, 2-AMINO-, 3-ETHYL 4-METHYL ESTER
• Synonyms: 3,4-THIOPHENEDICARBOXYLIC ACID, 2-AMINO-, 3-ETHYL 4-METHYL ESTER;2-Amino-3,4-thiophenedicarboxylic acid 3-ethyl 4-methyl ester;3-Ethyl 4-methyl 2-aminothiophene-3,4-dicarboxylate
• CAS NO: 844502-63-2
• Molecular Formula: C₉H₁₁NO₄S
• Molecular Weight: 229.255
• Mol File: 844502-63-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 102 °C
• Boiling Point: 328℃
• Flash Point: 152℃
• Appearance: /
• Density: 1.321
• PKA: -1.03±0.10(Predicted)
• CAS DataBase Reference: 3,4-THIOPHENEDICARBOXYLIC ACID, 2-AMINO-, 3-ETHYL 4-METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-THIOPHENEDICARBOXYLIC ACID, 2-AMINO-, 3-ETHYL 4-METHYL ESTER(844502-63-2)
• EPA Substance Registry System: 3,4-THIOPHENEDICARBOXYLIC ACID, 2-AMINO-, 3-ETHYL 4-METHYL ESTER(844502-63-2)

Safety Data

• Hazardous Substances Data: 844502-63-2(Hazardous Substances Data)

Usage

General Description

3,4-Thiophenedicarboxylic acid, 2-amino-, 3-ethyl 4-methyl ester is a chemical compound with the molecular formula C11H13NO4S. It is a derivative of thiophenedicarboxylic acid, which is commonly used in the synthesis of pharmaceuticals and agrochemicals. This particular compound is an ester of the 2-amino derivative of the acid, with ethyl and methyl substituents. It is used in organic synthesis and medicinal chemistry as a building block for the preparation of various compounds with potential pharmacological activity. Its specific properties and potential applications may vary depending on the context in which it is used.

Upstream product

• 600-22-6 pyruvic acid methyl ester 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 844502-64-3 2-bis-t-butoxycarbonylamino-thiophene-3,4-dicarboxylic acid-3-ethyl ester-4-methyl ester 
• 887511-47-9 3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate 
• 887511-48-0 3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate 
• 1257316-19-0 1-iodo-5-octyl-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione 
• 1257316-20-3 5,5'-dioctyl-4H,4'H-1,1'-bithieno[3,4-c]pyrrole-4,4',6,6'(5H,5'H)-tetrone 
• 1257316-21-4 3,3'-dibromo-5,5'-dioctyl l-4H,4'H-1,1'-bithieno[3,4-c]pyrrole-4,4',6,6'(5H,5'H)-tetrone 
• 1257316-22-5 1,1'-(2,1,3-benzothiadiazole-4,7-diyl)bis(5-octyl-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione) 
• 1257316-23-6 1,1'-(2,1,3-benzothiadiazole-4,7-diyl)bis(3-bromo-5-octyl-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione) 
• 1456890-49-5 tert-butyl (2-{[4-({[(4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)carbonyl]amino}methyl)benzyl]amino}ethyl)carbamate 
• 1456890-50-8 N-(4-{[(benzoylcarbamothioyl)amino]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-51-9 N-{4-[(carbamothioylamino)methyl]benzyl}-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-52-0 methyl N-[4-({[(4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)carbonyl]amino}methyl) benzyl]carbamimidothioate 
• 1456890-53-1 tert-butyl {1-[4-({[(4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)carbonyl]amino}methyl)benzyl]azetidin-3-yl}carbamate 
• 1456890-54-2 tert-Butyl 4-[4-({[(4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)carbonyl]amino}methyl) benzyl]piperazine-1-carboxylate 

Relevant articles and documents

Molecular Weight Engineering in High-Performance Ambipolar Emissive Mesopolymers

Mesopolymers with high solubility, free of structural defects, and negligible batch-to-batch variation open a new avenue for organic optoelectronics. Organic light emitting transistors that combine the functions of organic light-emitting diodes and organic field-effect transistors. However, charge transport ability and light emitting strength are contradictory within one conjugated polymer. Herein, three low-molecular-weight mesopolymers with thienopyrroledione–benzothiadiazole repeating units (meso-TBTF) were obtained. The mesopolymers show strong solid-state emission and high ambipolar carrier mobility. The molecular weights of meso-TBTF can be tuned by polymerization temperature. The mesopolymers have photoluminescence quantum yields (PLQY) of about 50 % in solution and 10 % in solid state. Polymer light emitting diodes of this material are fabricated to explore its potential use in optoelectronic devices.

Structural Insight into Aggregation and Orientation of TPD-Based Conjugated Polymers for Efficient Charge-Transporting Properties

In this study, we obtained a new structural insight into the charge-transporting properties in TPD-based polymers that cannot be solely explained in terms of the type of orientation. We synthesized two types of copolymers comprising mono-TPD or bis-TPD as the accepting unit. Although the planarity and energy levels are similar with the mono-TPD unit, the aggregation state is quite different, and the X-aggregation tendency seems to be stronger when the bis-TPD unit is incorporated. In the case of TPD1, an effective π-πorbital overlap is found to originate from the H-aggregates, and 3D charge transport pathways are formed with a bimodal orientation of edge-on and face-on, resulting in an efficient charge transportation (1.84 cm2·V-1·s-1 of hole and 0.31 cm2·V-1·s-1 of electron). In contrast, despite the well-aligned edge-on orientation of TPD2, it exhibited a relatively very low mobility and splitted emission characteristics in photoluminescence spectra because of the tilted intermolecular stacking pattern with an X-shape (0.015 cm2·V-1·s-1 for hole and 0.16 cm2·V-1·s-1 for electron). An overall characterization of the semiconducting polymers was performed, and it was found that the type of aggregation in the final thin films, such as H- or X-aggregation, is indeed important and perhaps more important than the orientation to obtain polymers with a high charge carrier mobility.

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.